Prognosis of acute myocardial infarction in the thrombolytic era: Medical evaluation is still valuable

European Journal of Heart Failure

Volumn 3, Issue 5, 2001, Pages 569-576

  Nicolau, José C ^a   Serrano, Carlos V ^a   Garzon, Sérgio A C ^b   Ramires, José A F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto de Molestias Cardiovasculares   (Brazil)

Author keywords

Acute myocardial infarction; Long term follow up; Medical evaluation; Thrombolysis

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CORRELATION ANALYSIS; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; SURVIVAL;

CORONARY ANGIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROGNOSIS; SURVIVAL RATE; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 0035740704     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(01)00170-2     Document Type: Article

References (36)

1. The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial
2. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2
4. Pre-hospital initiated vs. hospital initiated thrombolytic therapy: The myocardial infarction triage and intervention trial
5. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin
6. ISIS-3: A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and aspirin plus heparin vs. aspirin alone among 41299 cases of suspected acute myocardial infarction
7. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
8. Determinants of prognosis in survivors of myocardial infarction
9. The early posthospital phase of myocardial infarction: Prognostic stratification
10. Função ventricular esquerda na fase aguda de infartados submetidos aleatoriamente a 750000 ou 1.5 milhão de unidades de estreptoquinase
11. 2/prostaglandin endoperoxide receptor antagonist, vs. aspirin as adjunct to thrombolysis in patients with acute myocardial infarction
12. Thrombolysis In Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase
13. Temporal evolution of the human coronary collateral circulation after myocardial infarction
14. Preditores da sobrevida intra-hospitalar em pacientes infartados submetidos à terapêutica fibrinolítica (Predictors of in-hospital survival among infarcted patients submitted to fibrinolytic therapy)
15. Acute myocardial infarction treated with intravenous streptokinase: 6-Year follow-up
16. Correlative classification of clinical and hemodynamic function after acute myocardial infarction
17. Statistics
18. Cox's proportional hazards regression
19. Measurement of left ventricular function as an end point in trials of thrombolytic therapy
20. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function
21. Optimal level of filling pressure in the left side of the heart in acute myocardial infarction
22. Determinants of delay between symptoms and hospital admission in 5978 patients with acute myocardial infarction. Trandolapril cardiac evaluation
23. Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction
24. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: Results from an international trial of 41021 patients
25. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: Development of a predictive model
26. Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy
27. Insights derived from the Thrombolytics and Angioplasty In Myocardial Infarction (TAMI) Trials
28. Multivessel coronary artery disease: A key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction
29. The use of tissue-type-plasminogen activator for acute myocardial infarction in the elderly: Results from Thrombolysis in Myocardial Infarction Phase I, open-label studies and the Thrombolysis in Myocardial Infarction Phase II Pilot Study
30. Usefulness of the Killip classification for early risk stratification of patients with acute myocardial infarction in the 1990s compared with those treated in the 1980s
31. Follow-up of 2733 Japanese patients with myocardial infarction
32. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base
33. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
34. Early infarct artery collateral flow does not improve long-term survival following thrombolytic therapy for acute myocardial infarction
35. Prevention of congestive heart failure by early, prehospital thrombolysis in acute myocardial infarction
36. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction